Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVER-RECODE: Everolimus in Refractory Metastatic Colorectal Cancer With CDK12 Deficiency
NCT07435584Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of everolimus in colorectal cancer (CRC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
everolimus
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07435584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07435584.